Besides, PACSIN1 also downregulated in the mesenchymal molecular subtype group (Figure 4), suggesting that PACSIN1 would be a biomarker of the mesenchymal molecular subtype gliomas, with a more malignant phenotype and a worse prognosis. This evidence concerns the gene PACSIN1 and central nervous system cancer.